BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

...is intended for use with Advanced Accelerator’s marketed PET companion diagnostic, which is marketed as SomaKit...
BioCentury | Nov 3, 2017
Company News

Novartis offers $3.9B to acquire Advanced Accelerator

...gain Lutathera (177-Lu-Dotatate), a radiolabeled somatostatin analog that targets somatostatin receptors, and its companion diagnostics SomaKit...
...Basel, Switzerland Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint-Genis-Pouilly, France Business: Cancer Allison Johnson 177-Lu-Dotatate 177LU PSMA-R2 68GA PSMA-R2 Lutathera Netspot Sandostatin LAR Depot SomaKit...
BioCentury | Oct 30, 2017
Company News

Novartis offers $3.9B to acquire Advanced Accelerator

...gain Lutathera (177-Lu-Dotatate), a radiolabeled somatostatin analog that targets somatostatin receptors, and its companion diagnostics SomaKit...
...Medtronic plc (NYSE:MDT) acquired. Advanced Accelerator gained $7.59 (10%) to $80.50 on Monday. Allison Johnson 177-Lu-Dotatate 177LU PSMA-R2 68GA PSMA-R2 Afinitor Lutathera Netspot SomaKit...
BioCentury | Sep 26, 2016
Clinical News

SomaKit TOC edotreotide regulatory update

...EMA’s CHMP recommended approval of SomaKit TOC edotreotide from Advanced Accelerator for use in PET imaging...
...radiolabeling with a gallium-68 solution. Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: SomaKit...
BioCentury | Jun 13, 2016
Clinical News

Netspot regulatory update

...soon as possible.” Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: Netspot ( Somakit-TATE...
BioCentury | Nov 12, 2015
Top Story

IPO quartet pulls in combined $290.1M

...177Lu-DOTA0-Tyr3-octreotate) to treat midgut neuroendocrine tumors. Advanced Accelerator has already submitted applications for the candidate's Somakit...
BioCentury | Oct 2, 2015
Financial News

Advanced Accelerator revs up IPO plans again

...midgut neuroendocrine tumors. FDA already has granted Priority Review to an NDA for the company's Somakit...
...designation from FDA and EMA and Fast Track designation from FDA to treat neuroendocrine tumors. Somakit...
BioCentury | Sep 17, 2015
Clinical News

Advanced Accelerator's Lutathera meets in Phase III

...Vienna. The company also said FDA granted Priority Review to an NDA for the company's Somakit...
BioCentury | Jul 13, 2015
Finance

Accelerating investor interest

...in the U.S. and EU. This month, the company is also submitting an NDA for Somakit...
BioCentury | Jun 24, 2015
Financial News

Advanced Accelerator raises EUR 23M

...from FDA and EMA. The company also expects to file an NDA in July for Somakit...
Items per page:
1 - 10 of 10